Oncologic patients experience anemia and anemia is associated with poor prognosis. Transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality.
Between 36 and 75% of oncologic patients experience anemia and anemia is associated with poor prognosis. Up to 40% of surgical oncologic patients receive red blood cells (RBC). However, transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality. This is a retrospective, single center study. All adults admitted to the intensive care unit (ICU) after oncologic surgery within the study period are eligible.
Study Type
OBSERVATIONAL
Enrollment
300
CHRU de Brest, hôpital de la Cavale Blanche
Brest, France
RECRUITINGNumber of mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications
mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications
Time frame: 30 DAYS (hospital discharge)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.